<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384341</url>
  </required_header>
  <id_info>
    <org_study_id>19PH224</org_study_id>
    <secondary_id>2019-A03358-49</secondary_id>
    <nct_id>NCT04384341</nct_id>
  </id_info>
  <brief_title>Haemophilia and Bone Loss - PHILEOS Study</brief_title>
  <acronym>PHILEOS</acronym>
  <official_title>Haemophilia and Bone Loss PHILEOS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemophilia is a rare bleeding disorder, characterized by factor VIII (HA) or factor IX (HB)
      deficiency. The absence or the reduction of fVIII or fIX result in impaired thrombin
      generation and clot formation, causing excessive bleeding (mainly haemarthrosis).
      Osteoporosis is a systemic bone disease characterized by a low bone mineral density (BMD). A
      decrease of mean BMD has been described in haemophilic patients compared to healthy controls
      in several studies. So, osteoporosis could be an underestimated haemophilia-related
      comorbidity. None of the following risk factors (reduced physical activity, joint damage,
      vitamin D deficiency and /or hepatitis C virus (HCV) infection) has been retained as a cause
      of osteoporosis in haemophilic patients. Another hypothesis is that bone loss could be
      directly linked to fVIII or fIX and/or thrombin deficiency. The aim of this study is to
      evaluate the prevalence of the bone loss in HA and B patients, according to the type, the
      severity and the presence (or not) of a prophylactic treatment (depending on the age at which
      it was began) and to compare it to a control population. The investigators will also evaluate
      the relation between BMD and FVIII, fIX and thrombin potential.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and
      advertisements.

      Recruitment of haemophilic patients during a routine visit at the haemophilia centre.

      Information of the subjects that the study requires a BMD measure for all and a blood
      sampling for patients only.

      After inclusion and exclusion criteria have been checked, the subject can sign the consent.

      For all subjects, an appointment will be made for BMD measure. For patients and controls: BMD
      will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar
      spine (L2-L4) sites.

      For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic
      markers of bone remodelling will be measured centrally.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Osteoporosis defined by a T-score &lt; -2.5 in severe haemophilic patients without prophylaxis and in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteoporosis defined by a T-score &lt; -2.5 in the different groups of haemophilic patients and in in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteopenia defined by a T-score &lt; -1 in the different groups of haemophilic patients and in in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (expressed as a T-score) in the different groups of haemophilic patients and in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal level of fVIII/fIX (expressed as an Ag level or as a %) or thrombin generation potential (expressed as an endogenous thrombin potential (ETP), nmol/min)</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Blood test Relation between the basal level of fVIII or fIX (expressed as an Ag level or as a %) or the thrombin generation potential (expressed as an endogenous thrombin potential (ETP), nmol/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers influencing bone metabolism in all haemophilic patients included</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Haemophilic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling Bone Densitometry (BMD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone Densitometry (BMD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Bone densitometry (BMD)</intervention_name>
    <description>Recruitment of haemophilic patients during a routine visit at the haemophilia centre.
Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.
After inclusion and exclusion criteria have been checked, the subject can sign the consent.
For all subjects, an appointment will be made for BMD measure.
For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.
Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.</description>
    <arm_group_label>Haemophilic patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling for patients only</intervention_name>
    <description>For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.</description>
    <arm_group_label>Haemophilic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers :

               -  Healthy men aged between 20 to 60 years old

          -  Haemophilic Patients:

               -  Haemophilia A and B patients, irrespective of the disease form (mild, moderate,
                  severe with or without prophylaxis)

               -  Haemophilic patients aged between 20 to 60 years old

               -  Severe Haemophilia A patients with prophylaxis : last factor VIII injection more
                  than 96 to 120 hours (depending on on the prophylactic treatment) prior blood
                  sampling dedicated to the this research

               -  Severe Haemophilia B patients : last factor IX injection more than 5 to 21 days
                  (depending on the prophylactic treatment) prior blood sampling dedicated to the
                  this research

        Exclusion Criteria:

          -  Healthy Volunteers:

               -  History of disease known to influence bone metabolism (hyperthyroidism,
                  hyperparathyroidism, hypercorticism, hypogonadism, diseases that require
                  long-term use of corticoids, …)

               -  Past or present treatment with any osteoporotic medication other than Vit D or
                  Ca++

               -  Presence of two total hip prostheses

               -  HIV documented infection

               -  HCV documented infection (in progress or cured) at cirrhotic stage

          -  Haemophilic Patients:

               -  Haemophilic patients with current or history of inhibitor anti-fVIII or anti-fIX
                  (&gt;5 Bethesda Units)

               -  History of disease known to influence bone metabolism and not related to
                  haemophilia (hyperthyroidism, hyperparathyroidism, hypercorticism, hypogonadism,
                  diseases that require long-term use of corticoids, …)

               -  Past or present treatment with any anti-osteoporotic medication other than Vit D
                  or Ca++

               -  Presence of two total hip prostheses

               -  HIV documented infection

               -  HCV documented infection (in progress or cured) at cirrhotic stage
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte TARDY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte TARDY, MD-PhD</last_name>
    <phone>0477421877</phone>
    <email>brigitte.tardy@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fleur PETIT, CRA</last_name>
    <phone>0477120826</phone>
    <email>fleur.petit@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu de Bordeaux</name>
      <address>
        <city>Bourdeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SABINE CASTET</last_name>
    </contact>
    <investigator>
      <last_name>SABINE CASTET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Brest Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BRIGITTE PAN-PETESCH</last_name>
    </contact>
    <investigator>
      <last_name>BRIGITTE PAN-PETESCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Metropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>VALERIE GAY</last_name>
    </contact>
    <investigator>
      <last_name>ROMAIN JAILLER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>VALERIE GAY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Cth Estaing Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>AURELIEN LEBRETON</last_name>
    </contact>
    <investigator>
      <last_name>AURELIEN LEBRETON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FABIENNE GENRE-VOLLOT</last_name>
    </contact>
    <investigator>
      <last_name>FABIENNE GENRE-VOLLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BENOIT POLACK</last_name>
    </contact>
    <investigator>
      <last_name>RAPHAEL MARLU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BENOIT POLACK</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu La Timone Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HERVE CHAMBOST</last_name>
    </contact>
    <investigator>
      <last_name>CELINE FALAISE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HERVE CHAMBOST</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Necker Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LAURENT FRENZEL</last_name>
    </contact>
    <investigator>
      <last_name>LAURENT FRENZEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rennes Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BENOIT GUILLET</last_name>
    </contact>
    <investigator>
      <last_name>BENOIT GUILLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PIERRE CHAMOUNI</last_name>
    </contact>
    <investigator>
      <last_name>PIERRE CHAMOUNI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BRIGITTE TARDY</last_name>
    </contact>
    <investigator>
      <last_name>THIERRY THOMAS, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BRIGITTE TARDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DOMINIQUE DESPREZ</last_name>
    </contact>
    <investigator>
      <last_name>DOMINIQUE DESPREZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>fVIII</keyword>
  <keyword>fIX</keyword>
  <keyword>thrombin</keyword>
  <keyword>Haemophilia</keyword>
  <keyword>Hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

